<DOC>
	<DOCNO>NCT00307034</DOCNO>
	<brief_summary>Assess immuno , reacto 10-valent pneumococcal vaccine 2 dos ( 2 , 4 month age ) complete 2 , 4 , 11 month schedule co-administered DTPa-HBV-IPV/Hib DTPa-IPV/Hib ( accord national recommendation )</brief_summary>
	<brief_title>Safety &amp; Immunogenicity Study 10-Valent Pneumococcal Conjugate Vaccine When Administered 2-Dose Schedule</brief_title>
	<detailed_description>Total anticipate : 300 subject ( 150/group ) . 2-dose group - 10-valent pneumococcal vaccine + DTPa combine vaccine ( 2 , 4 , 11 month ) ; Comparator group - 10-valent pneumococcal vaccine ( 2 , 3 , 4 , 11 month ) + DTPa combine vaccine ( 2 , 4 , 11 month ) . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criterion : Subjects investigator believe parents/guardians comply requirement protocol . A male female , include , 8 16 week ( 56120 day ) age time first vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Born gestation period 36 42 week . Exclusion criterion : Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Planned administration/ administration vaccine foreseen study protocol period start 30 day first dose vaccine ( ) end 30 day last dose , exception BCG vaccination give 1 month postdose 2 3 ( 2411 23411 month age schedule ) blood sample minimum 30 day prebooster dose blood sampling . Previous vaccination diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b , and/or S. pneumoniae . History intercurrent diphtheria , tetanus , pertussis , hepatitis B , polio , Haemophilus influenzae type b disease , and/or invasive pneumococcal disease . History allergic disease reaction likely exacerbate component vaccine . History neurologic disorder seizure . Acute disease time enrolment . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination A family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . Administration immunoglobulins and/or blood product since birth plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primary vaccination</keyword>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Safety</keyword>
	<keyword>Booster vaccination</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Dose comparison</keyword>
</DOC>